###begin article-title 0
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 388 394 388 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6</italic>
###xml 422 429 422 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1</italic>
###xml 500 509 500 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 513 523 513 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 613 620 613 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 624 632 624 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
###xml 653 661 <span type="species:ncbi:9606">patients</span>
Tamoxifen is widely used as endocrine therapy for oestrogen-receptor-positive breast cancer. However, many of these patients experience recurrence despite tamoxifen therapy by incompletely understood mechanisms. In the present report we propose that tamoxifen resistance may be due to differences in activity of metabolic enzymes as a result of genetic polymorphism. Cytochrome P450 2D6 (CYP2D6) and sulfotransferase 1A1 (SULT1A1) are polymorphic and are involved in the metabolism of tamoxifen. The CYP2D6*4 and SULT1A1*2 genotypes result in decreased enzyme activity. We therefore investigated the genotypes of CYP2D6 and SULT1A1 in 226 breast cancer patients participating in a trial of adjuvant tamoxifen treatment in order to validate the benefit from the therapy.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 4 12 <span type="species:ncbi:9606">patients</span>
The patients were genotyped using PCR followed by cleavage with restriction enzymes.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 16 25 16 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 164 166 164 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 214 224 214 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 296 298 296 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 327 336 327 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 343 356 343 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1/*1 </italic>
###xml 525 527 525 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 387 395 <span type="species:ncbi:9606">patients</span>
Carriers of the CYP2D6*4 allele demonstrated a decreased risk of recurrence when treated with tamoxifen (relative risk = 0.28, 95% confidence interval = 0.11-0.74, P = 0.0089). A similar pattern was seen among the SULT1A1*1 homozygotes (relative risk = 0.48, 95% confidence interval = 0.21-1.12, P = 0.074). The combination of CYP2D6*4 and/or SULT1A1*1/*1 genotypes comprised 60% of the patients and showed a 62% decreased risk of distant recurrence with tamoxifen (relative risk = 0.38, 95% confidence interval = 0.19-0.74, P = 0.0041).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 154 162 <span type="species:ncbi:9606">patients</span>
The present study suggests that genotype of metabolic enzymes might be useful as a guide for adjuvant endocrine treatment of postmenopausal breast cancer patients. However, results are in contradiction to prior hypotheses and the present sample size is relatively small. Findings therefore need to be confirmed in a larger cohort.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 144 152 <span type="species:ncbi:9606">patients</span>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
The majority of breast tumours express oestrogen receptors (ERs). Several studies have shown that 5 years of tamoxifen therapy in breast cancer patients with receptor-positive tumours reduces the risk of recurrence and mortality [1]. However, about 30% of patients acquire tamoxifen resistance and relapse in the disease [1]. Several possible mechanisms for this have been suggested [2-4].
###end p 11
###begin p 12
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 500 501 496 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 532 533 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 701 702 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 703 704 699 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 856 857 852 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 858 859 854 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1269 1271 1265 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1272 1274 1268 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1150 1155 <span type="species:ncbi:9606">human</span>
Tamoxifen and its metabolites compete with endogenous oestrogen for the ligand-binding domain of the ER. The complex formation between tamoxifen, or its active metabolites, and the ER inhibits recruitment of co-activator complexes necessary for transcription of oestrogen-responsive genes [5]. The biotransformation of tamoxifen is mediated by cytochrome P450 enzymes mainly through demethylation and hydroxylation to form several primary metabolites, principally 4-OH-tamoxifen, alpha-OH-tamoxifen, N-desmethyl-tamoxifen, and 4-OH-N-desmethyl-tamoxifen. 4-OH-tamoxifen is considered to be a more potent anti-oestrogen than the mother substance and is capable of binding the ER with greater affinity [6,7]. From experimental studies it has been shown that the transformation of tamoxifen into 4-OH-tamoxifen is mainly catalysed by the liver enzyme CYP2D6 [8,9]. A further step in the metabolism of tamoxifen is sulfate conjugation, catalysed by members of the sulfotransferase family, which generally increase the solubility and facilitate excretion of the drug. Sulfotransferase 1A1 (SULT1A1) is a major form of phenol sulfotransferase in the adult human liver, and it has been shown to be the primary sulfotransferase responsible for the sulfation of 4-OH-tamoxifen [10,11].
###end p 12
###begin p 13
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6</italic>
###xml 101 109 101 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 182 189 182 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 196 205 196 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 362 364 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 403 411 401 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 556 565 552 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2</italic>
###xml 637 639 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 707 714 703 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 718 726 714 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 743 751 <span type="species:ncbi:9606">patients</span>
Polymorphisms affecting the enzyme activity have been found in both cytochrome P450 2D6 (CYP2D6) and SULT1A1 [12,13]. Among Caucasians the most frequent inactivating polymorphism in CYP2D6 is the CYP2D6*4 allele, which generates a G --> A transition at nucleotide 1934 leading to a disruption of the reading frame and to a truncated non-functional gene product [14]. The most common polymorphism in the SULT1A1 gene is a G --> A transition at nucleotide 638, resulting in an arginine to histidine substitution at the conserved amino acid 213. This allele, SULT1A1*2, is correlated with diminished capacity to sulfate SULT1A1 substrates [15]. The aim of the present study was to investigate the genotypes of CYP2D6 and SULT1A1 in breast cancer patients with and without tamoxifen treatment in order to validate the relation between the genotype and the benefit from tamoxifen therapy.
###end p 13
###begin title 14
Materials and methods
###end title 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 15
###begin p 16
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
###xml 389 397 <span type="species:ncbi:9606">patients</span>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
###xml 978 986 <span type="species:ncbi:9606">patients</span>
###xml 1045 1053 <span type="species:ncbi:9606">patients</span>
The Stockholm Breast Cancer Group started a trial in 1976 to compare postoperative radiotherapy with adjuvant chemotherapy [16]. Both premenopausal patients and postmenopausal patients (age </= 70 years) with a unilateral, operable breast cancer were included. The patients were required to have either histological verified lymph node metastases or a tumour diameter exceeding 30 mm. All patients were treated with a modified radical mastectomy. Using a 2 x 2 factorial study design, the postmenopausal patients were then randomised to a comparison of adjuvant tamoxifen treatment or no endocrine treatment in a total of four treatment groups: adjuvant chemotherapy, adjuvant chemotherapy plus tamoxifen, radiotherapy, and radiotherapy plus tamoxifen. Tamoxifen was given postoperatively at a dose of 40 mg daily for 2 years and was initiated within 4-6 weeks of surgery. The mean follow-up time was 10.7 years (range, 0.24-18.6 years). Of the 679 postmenopausal breast cancer patients included in the trial, fresh frozen tumour tissues of 226 patients were available for the current investigation, of whom 112 had received tamoxifen therapy. The number of distant recurrences was 64 in the tamoxifen-treated group and 84 in the group not receiving tamoxifen. Furthermore, the fractions of lymph-node-positive and ER-positive tumours were 88/89 and 71/70, respectively, and the percentage of large tumours (>20 mm) was 57/61 in the initial study and the current study.
###end p 16
###begin title 17
Polymerase chain reaction
###end title 17
###begin p 18
###xml 178 185 178 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 189 197 189 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 334 341 334 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 345 353 345 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 513 514 512 513 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 540 544 539 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
DNA was isolated from fresh-frozen tumour tissues using phenol, phenol/chloroform (1:1), and chloroform, was precipitated with ethanol and was re-dissolved in sterile water. The CYP2D6 and SULT1A1 genes were amplified with PCR in separate reactions using 30 ng DNA and 60 ng DNA, respectively. The primer sequences used in the PCR of CYP2D6 and SULT1A1 were adopted from Hanioka and colleagues [14] and Coughtrie and colleagues [17]. The following PCR reagents were added to a reaction volume of 20 mul: 2 mM MgCl2, 0.2 mM dNTPs, 0.5 units Taq DNA polymerase, and 1 muM each of forward and reverse primer in 1 x PCR buffer. The amplifications were carried out in a PTC-200 Peltier Thermal Cycler DNA Engine (MJ Researchtrade mark Inc, Waltham, MA, USA). An initial denaturation at 94degreesC for 3 min was followed by 40-43 cycles of 30 s at 94degreesC, 30 s of annealing at 63degreesC, and 40 s for extension at 72degreesC. An extension period of 5 min followed the final cycle.
###end p 18
###begin title 19
Restriction fragment length polymorphism
###end title 19
###begin p 20
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 15 23 15 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 82 85 82 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mva</italic>
###xml 120 129 120 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 146 153 146 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 185 194 185 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 286 289 286 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mva</italic>
###xml 353 361 353 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1</italic>
###xml 363 373 363 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 433 436 433 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hae</italic>
###xml 469 479 469 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
The CYP2D6 and SULT1A1 polymorphisms were detected using restriction enzymes. The MvaI enzyme distinguishes between the CYP2D6*4 allele and other CYP2D6 alleles. The polymorphic allele CYP2D6*4 lacks the restriction site, and is thereby retained as one fragment. Alleles harbouring the MvaI restriction site generate two fragments and are classified as CYP2D6*1. SULT1A1*1 (wild-type allele) has a restriction site recognised by the HaeII enzyme, while the polymorphic SULT1A1*2 lacks this site.
###end p 20
###begin p 21
###xml 13 16 13 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mva</italic>
###xml 62 64 61 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 110 117 109 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 182 190 175 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 257 260 250 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hae</italic>
Ten units of MvaI (Fermentas, Stockholm, Sweden) and 1.5 mul R+ Buffer (Fermentas) were added to each tube of CYP2D6 PCR products and were incubated at 37degreesC for 2.5 hours. The SULT1A1 PCR products were incubated with 5 units of the restriction enzyme HaeII (New England BioLabs, Beverly, MA, USA) in a 20 mul reaction mixture containing 1 x NE (50 mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium acetate, 1 mM dithiothreitol, pH 7.9) buffer (New England Bioloabs), supplemented with 100 mug/ml BSA. After digestion, fragments were resolved by electrophoresis on a 3% (w/v) agarose gel containing 1 x TBE (89 mM Tris, 89 mM Boric acid, 2 mM EDTA, pH 8.4) buffer and ethidium bromide (0.5 mug/mul). A 100-molecule weigh ladder was used as the base pair marker. The gel was finally processed in a UV detector (Spectromics Corporation, New York, USA). To confirm the reliability of the restriction fragment length polymorphism method, a number of randomly selected samples were DNA sequenced. No differences in genotype were obtained between the methods.
###end p 21
###begin title 22
Statistical analyses
###end title 22
###begin p 23
###xml 282 290 <span type="species:ncbi:9606">patients</span>
Statistical analyses were performed with the Statistica 6.0 software program (Statsoft Inc., Tulsa, OK, USA). We compared distant recurrence-free survival by genotype and by endocrine treatment with the log-rank test. The relative risk (RR) of distant recurrences among ER-positive patients treated with and without tamoxifen was assessed using Cox proportional hazard regression, and adjustments for age, tumour size, and lymph node status were performed.
###end p 23
###begin title 24
Results
###end title 24
###begin p 25
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 165 174 165 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 182 192 182 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 195 205 195 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
Information on tumour size, nodal involvement, ER status and tamoxifen therapy of 226 patients is presented in Table 1. The patients were genotyped according to the CYP2D6*4 and the SULT1A1*1 or SULT1A1*2 alleles. There were no significant differences in tumour characteristics between genotypes (Table 1).
###end p 25
###begin p 26
###xml 65 74 65 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 78 87 78 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2</italic>
###xml 113 122 113 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 171 180 171 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 263 273 263 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 461 470 461 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1 </italic>
###xml 513 522 513 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 566 576 566 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 618 628 618 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 144 152 <span type="species:ncbi:9606">patients</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
###xml 538 546 <span type="species:ncbi:9606">patients</span>
###xml 853 861 <span type="species:ncbi:9606">patients</span>
The distributions of allele frequencies were 0.163 and 0.386 for CYP2D6*4 and SULT1A1*2, respectively. Since the CYP2D6*4 homozygotes were few, patients with at least one CYP2D6*4 allele were combined in the statistical analyses. Similarly, patients carrying the SULT1A1*2 allele were grouped together. To investigate whether the genotype had a prognostic value, in terms of distant recurrence-free survival, ER-positive and ER-negative patients homozygous for CYP2D6*1 alleles were compared with carriers of the CYP2D6*4 allele, and the patients homozygous for the SULT1A1*1 allele were compared with carriers of the SULT1A1*2 allele. No statistical differences in distant recurrences were found according to genotype (data not shown). To assess the benefit from tamoxifen treatment, distant recurrence-free survival was only calculated in ER-positive patients.
###end p 26
###begin p 27
###xml 37 46 37 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1 </italic>
###xml 63 72 63 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 107 117 107 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 138 148 138 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 196 200 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a,b</xref>
###xml 205 209 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a,b</xref>
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 288 297 288 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 411 413 411 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 579 588 579 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1 </italic>
###xml 696 698 696 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 771 781 771 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 880 882 880 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 1041 1051 1041 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 1059 1061 1059 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1075 1077 1075 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 255 263 <span type="species:ncbi:9606">Patients</span>
###xml 551 559 <span type="species:ncbi:9606">patients</span>
###xml 686 694 <span type="species:ncbi:9606">patients</span>
###xml 792 800 <span type="species:ncbi:9606">patients</span>
Distant recurrence-free survival for CYP2D6*1 homozygotes, for CYP2D6*4 heterozygotes and homozygotes, for SULT1A1*1 homozygotes, and for SULT1A1*2 heterozygotes and homozygotes are shown in Figs 1a,b and 2a,b, respectively, and are presented in Table 2. Patients possessing at least one CYP2D6*4 allele had better survival when randomised to tamoxifen compared with those who were not randomised to tamoxifen (P = 0.0089), as also demonstrated by the significantly decreased relative risk (RR = 0.28, 95% confidence interval [CI] = 0.11-0.74). Among patients homozygous for the CYP2D6*1 genotype, the outcome was approximately equal between tamoxifen-treated and non-tamoxifen-treated patients (P = 0.75). A tendency towards improved distant recurrence-free survival in SULT1A1*1 homozygous patients treated with tamoxifen, compared with those receiving no tamoxifen, was found (P = 0.074, RR = 0.48, 95% CI = 0.21-1.12) (Fig. 2a). Finally, no influence of tamoxifen therapy on distant recurrence-free survival was found in carriers of the SULT1A1*2 allele (P = 0.48) (Fig. 2b).
###end p 27
###begin p 28
###xml 82 83 82 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 164 173 164 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 200 209 200 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1</italic>
###xml 264 266 264 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 354 363 354 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1 </italic>
###xml 379 389 379 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 477 479 477 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 779 788 779 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 795 808 795 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1/*1 </italic>
###xml 809 811 809 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 826 830 826 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a,b</xref>
###xml 841 842 841 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 740 748 <span type="species:ncbi:9606">patients</span>
The genotypes linked to the benefit from tamoxifen treatment are combined in Fig. 3 as well as in Table 2. In patients harbouring the combination with at least one CYP2D6*4 allele and/or a homozygous SULT1A1*1, tamoxifen treatment significantly improved survival (P = 0.0041, RR = 0.38, 95% CI = 0.19-0.74). We also compared non-beneficial alleles (i.e. CYP2D6*1 homozygotes and SULT1A1*2 carriers), and no statistical difference was found in distant recurrence-free survival (P = 0.57, RR = 1.22, 95% CI = 0.61-2.4). A comparison of the RRs of distant recurrence, calculated for each combined genotype and adjusted for age, tumour size and lymph node status, demonstrated that the risk reduction with tamoxifen was significantly higher in patients harbouring the combination of CYP2D6*4 and/or SULT1A1*1/*1 (P = 0.018) (Fig. 3a,b and Table 2).
###end p 28
###begin title 29
Discussion
###end title 29
###begin p 30
###xml 85 94 85 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 132 142 132 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 143 145 143 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 197 206 197 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1 </italic>
###xml 226 236 226 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 249 250 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 319 326 319 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 384 394 384 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 573 583 573 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1015 1017 1015 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
We observed a significantly improved benefit from tamoxifen in patients carrying the CYP2D6*4 allele and/or patients homozygous for SULT1A1*1 (P = 0.018), compared with patients homozygous for the CYP2D6*1 and carriers of the SULT1A1*2 allele (Fig. 3). To our knowledge this is the first report of the influence of the CYP2D6 genotype on tamoxifen therapy, while the influence of the SULT1A1*1 allele has been investigated by Nowell and colleagues [13]. In agreement with the tendency found in the present report, Nowell and colleagues showed that the high-activity allele SULT1A1*1 contributed significantly to tamoxifen response [13]. Those authors suggested that sulfation may affect bioavailability of 4-OH-tamoxifen by reduced clearance of the sulfated metabolite. This may provide a genotype-dependent reservoir of inactivated metabolite, which can be desulfated by steroid sulfatase expressed in breast tumours and can be recovered to the active 4-OH-tamoxifen, leading to a prolonged anti-oestrogen effect [18].
###end p 30
###begin p 31
###xml 23 25 23 25 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 46 47 46 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 48 49 48 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 102 109 102 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 559 568 559 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 660 669 660 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1 </italic>
###xml 730 739 730 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1 </italic>
###xml 1238 1240 1238 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1241 1243 1241 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 491 499 <span type="species:ncbi:9606">patients</span>
###xml 532 540 <span type="species:ncbi:9606">patients</span>
###xml 632 640 <span type="species:ncbi:9606">patients</span>
###xml 750 758 <span type="species:ncbi:9606">patients</span>
###xml 932 940 <span type="species:ncbi:9606">patients</span>
Coller and colleagues [19] and other workers [8,9] have demonstrated in experimental studies that the CYP2D6 genotype is a determinant of the ability to form 4-OH-tamoxifen. However, a clinical study by Stearns and colleagues [20] revealed that inhibition of CYP2D6 had no significant effect on 4-OH-tamoxifen concentration. We propose in the present study that genotypes of CYP2D6, which produce a large amount of the ER-active 4-OH-tamoxifen, would be beneficial for the tamoxifen-treated patients. As shown in the present study, patients with at least one CYP2D6*4 allele demonstrated better response to tamoxifen treatment than patients homozygous for the CYP2D6*1 allele. This is in contrast to the main hypotheses where the CYP2D6*1 homozygous patients are supposed to generate the active metabolite 4-OH-tamoxifen more readily and thereby have improved response of tamoxifen. Our results were obtained from a small number of patients, and therefore the association of the genotype and the benefit of tamoxifen treatment may be a coincidence. An absent or decreased CYP2D6-dependent 4-hydroxylation is, however, compensated by CYP2C9 and CYP3A4 to the overall formation of 4-OH-tamoxifen, but the reaction proceeds at a lower rate [19,21].
###end p 31
###begin p 32
###xml 63 64 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 425 426 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 571 578 571 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 346 352 <span type="species:ncbi:9606">humans</span>
###xml 501 507 <span type="species:ncbi:9606">humans</span>
Interestingly, an additional active tamoxifen metabolite, 4-OH-N-desmethyl-tamoxifen (endoxifen), has been recently discovered by Stearns and colleagues [20]. Endoxifen may have clinical relevance since the metabolite inhibits MCF7 cell proliferation with equal potency as does 4-OH-tamoxifen, and it is present in higher plasma concentration in humans than 4-OH-tamoxifen. Endoxifen is mainly synthesised by CYP3A4-mediated N-demethylation of tamoxifen and a subsequent 4-hydroxylation by CYP2D6. In humans there are a large number of different polymorphic sites in the CYP2D6 gene, and the vast majority is present in a very low frequency.
###end p 32
###begin p 33
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6</italic>
###xml 94 103 94 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 207 216 207 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*3 </italic>
###xml 220 228 220 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*5</italic>
###xml 282 289 282 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 352 362 352 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*41 </italic>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 553 562 553 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 598 605 598 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 667 676 667 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*3 </italic>
###xml 680 689 680 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*5 </italic>
###xml 798 807 798 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1 </italic>
###xml 880 889 880 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1 </italic>
###xml 893 901 893 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*2</italic>
###xml 970 972 970 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1014 1023 1014 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 1097 1106 1097 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 1393 1402 1393 1402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 1474 1476 1474 1476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1106 1114 <span type="species:ncbi:9606">patients</span>
In the present study we screened for the most common inactivating polymorphism in CYP2D6, the CYP2D6*4 allele, which is present at a frequency of approximately 21-29%. Other less common inactive alleles are CYP2D6*3 and CYP2D6*5, representing around 1% and 4%, respectively, of all CYP2D6 alleles [22]. Among alleles with decreased enzyme activity the CYP2D6*41 allele identifies a large proportion of the intermediate metabolisers [23]. The restriction fragment length polymorphism technique that we used identifies a restriction site not found in the CYP2D6*4 allele but that is present in other CYP2D6 alleles. This results in misclassification of the carriers of CYP2D6*3 and CYP2D6*5 alleles, which could occur in a few cases but would have a minor influence on the results. The definition of CYP2D6*1 used in the present study mainly constitutes the normal activity alleles CYP2D6*1 and CYP2D6*2, which represent a rather high frequency in a Caucasian population [22]. In the regression analysis we combined CYP2D6*4 heterozygotes and homozygotes in one group since the number of homozygous CYP2D6*4 patients was low. Some studies have shown that the hydroxylation ratios are significantly different between the homozygous and heterozygous genotypes, demonstrating intermediate hydroxylation ratios in heterozygous genotypes. There is also support, however, for the hypothesis that only CYP2D6*4 homozygotes will demonstrate altered pharmacokinetics for a given drug [24].
###end p 33
###begin title 34
Conclusion
###end title 34
###begin p 35
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
The variability in distant recurrence-free survival found in endocrine-treated patients may be a result of differences in drug metabolism. The genotype of metabolic enzymes might thus be useful as a guide for adjuvant endocrine treatment of postmenopausal breast cancer patients. However, our results contradict the main hypotheses and the present sample size is relatively small. Our findings therefore need confirmation in a larger cohort.
###end p 35
###begin title 36
Abbreviations
###end title 36
###begin p 37
###xml 6 12 <span type="species:ncbi:9913">bovine</span>
BSA = bovine serum albumin; CI = confidence interval; CYP2D6 = cytochrome P450 2D6; ER = oestrogen receptor; PCR = polymerase chain reaction; RR = relative risk; SULT1A1 = sulfotransferase 1A1.
###end p 37
###begin title 38
Competing interests
###end title 38
###begin p 39
The author(s) declare that they have no competing interests.
###end p 39
###begin title 40
Authors' contribution
###end title 40
###begin p 41
PW carried out part of the laboratory work and drafted the manuscript. LV carried out part of the laboratory work. OS contributed with the coordination of tumour material and performed the statistical analyses. BN initiated the randomised clinical trial. LS and L-ER provided tumour material and clinical data. SW conceived the study and participated in its design and coordination. All authors read and approved the final version of the manuscript.
###end p 41
###begin title 42
Acknowledgements
###end title 42
###begin p 43
This project was supported by grants from The Swedish Cancer and Allergy Society and from The Foundation of the National Board of Health and Welfare.
###end p 43
###begin article-title 44
Tamoxifen for early breast cancer: an overview of the randomised trials
###end article-title 44
###begin article-title 45
Hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions
###end article-title 45
###begin article-title 46
Enhanced epidermal growth factor receptor signalling in MCF-7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex)*
###end article-title 46
###begin article-title 47
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 Cells
###end article-title 47
###begin article-title 48
Endocrine-responsive breast cancer and strategies for combating resistance
###end article-title 48
###begin article-title 49
###xml 125 130 <span type="species:ncbi:9606">human</span>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer
###end article-title 49
###begin article-title 50
Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth
###end article-title 50
###begin article-title 51
###xml 46 51 <span type="species:ncbi:9606">human</span>
CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver
###end article-title 51
###begin article-title 52
Identification of CYP forms involved in the activation of tamoxifen and irreversible binding to DNA
###end article-title 52
###begin article-title 53
###xml 31 36 <span type="species:ncbi:9606">human</span>
Steroid sulfation by expressed human cytosolic sulfotransferases
###end article-title 53
###begin article-title 54
Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer
###end article-title 54
###begin article-title 55
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences
###end article-title 55
###begin article-title 56
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy
###end article-title 56
###begin article-title 57
###xml 84 89 84 89 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1934 </sub>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934 --> A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site
###end article-title 57
###begin article-title 58
###xml 44 50 <span type="species:ncbi:9606">humans</span>
Phenol sulfotransferase pharmacogenetics in humans: Association of common SULT1A1 alleles with TS PST phenotype
###end article-title 58
###begin article-title 59
Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials
###end article-title 59
###begin article-title 60
Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations
###end article-title 60
###begin article-title 61
###xml 49 62 <span type="species:ncbi:9544">rhesus monkey</span>
The metabolism of estrone sulphate in the female rhesus monkey
###end article-title 61
###begin article-title 62
###xml 124 129 <span type="species:ncbi:9606">human</span>
The influence of CYP2B6, CYP2C9, and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver
###end article-title 62
###begin article-title 63
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
###end article-title 63
###begin article-title 64
###xml 97 102 <span type="species:ncbi:9606">human</span>
Variable contribution of cytochrome P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes
###end article-title 64
###begin article-title 65
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants
###end article-title 65
###begin article-title 66
Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6
###end article-title 66
###begin article-title 67
Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency
###end article-title 67
###begin title 68
Figures and Tables
###end title 68
###begin p 69
###xml 128 135 128 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 287 291 287 291 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 319 328 319 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1 </italic>
###xml 405 408 405 408 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 454 463 454 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 54 59 <span type="species:ncbi:9606">women</span>
###xml 190 198 <span type="species:ncbi:9606">patients</span>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
###xml 291 299 <span type="species:ncbi:9606">Patients</span>
###xml 410 418 <span type="species:ncbi:9606">Patients</span>
Distant recurrence-free survival among postmenopausal women with oestrogen-receptor-positive breast cancers, in relation to the CYP2D6 genotype and adjuvant tamoxifen treatment. Solid line, patients receiving tamoxifen (Tam+); dashed line, patients who did not receive tamoxifen (Tam-). (a) Patients homozygous for the CYP2D6*1 allele. The number of events for Tam+ and Tam- were 25 and 27, respectively. (b). Patients homozygous or heterozygous for the CYP2D6*4 allele (null allele). The number of events for Tam+ and Tam- were 6 and 15, respectively.
###end p 69
###begin p 70
###xml 122 130 122 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 280 284 280 284 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 312 322 312 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 398 402 398 402 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 446 456 446 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
###xml 284 292 <span type="species:ncbi:9606">Patients</span>
###xml 402 410 <span type="species:ncbi:9606">Patients</span>
Distant recurrence-free survival of postmenopausal, oestrogen-receptor-positive breast cancer patients in relation to the SULT1A1 genotype and adjuvant tamoxifen therapy. Solid line, patients receiving tamoxifen (Tam+); dashed line, patients who did not receive tamoxifen (Tam-). (a) Patients homozygous for the SULT1A1*1 allele. The number of events for Tam+ and Tam- were 9 and 16, respectively. (b) Patients homozygous or heterozygous for the SULT1A1*2 allele (low-activity allele). The number of events for Tam+ and Tam- were 24 and 26, respectively.
###end p 70
###begin p 71
###xml 296 300 296 300 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 328 338 328 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 387 396 387 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 473 477 473 477 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 505 514 505 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1 </italic>
###xml 560 570 560 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 817 819 817 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 185 193 <span type="species:ncbi:9606">patients</span>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
###xml 300 308 <span type="species:ncbi:9606">Patients</span>
###xml 477 485 <span type="species:ncbi:9606">Patients</span>
Distant recurrence-free survival of postmenopausal, oestrogen-receptor-positive breast cancer patients with genotypes linked to the benefit from adjuvant tamoxifen therapy. Solid line, patients treated with tamoxifen (Tam+); dashed line, patients not receiving adjuvant tamoxifen therapy (Tam-). (a) Patients homozygous for the SULT1A1*1 allele and/or homozygous or heterozygous for the CYP2D6*4 allele. The number of events for Tam+ and Tam- were 15 and 27, respectively. (b) Patients homozygous for the CYP2D6*1 allele and homozygous or heterozygous for the SULT1A1*2 allele. The number of events for Tam+ and Tam- were 15 and 18, respectively. The relative risk for distant recurrence was calculated for each genotype; when compared, a significant decrease in relative risk was found for the beneficial genotypes (P = 0.018).
###end p 71
###begin p 72
###xml 86 88 86 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 160 168 <span type="species:ncbi:9606">patients</span>
Genotype, tumour characteristics and endocrine therapy of the total study population (n = 226), including both oestrogen receptor (ER)-positive and ER-negative patients
###end p 72
###begin p 73
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aNodal involvement: node+, node-positive; node-, node-negative.
###end p 73
###begin p 74
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
bER data from three patients were missing.
###end p 74
###begin p 75
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Statistics of oestrogen-receptor-positive patients: association between tamoxifen therapy/no tamoxifen therapy (Tam+/Tam-) and distant recurrence rate, stratified according to genotype
###end p 75
###begin p 76
The relative risks of distant recurrence, calculated for each combined genotype are adjusted for age, tumour size and lymph node status.
###end p 76
###begin p 77
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
aFollow-up data of two patients were missing.
###end p 77
###begin p 78
###xml 0 33 0 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;,&#8225;,&#167;</sup>
###xml 214 220 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 220 222 187 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 230 243 197 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8225;</sup>
###xml 243 245 198 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 258 270 213 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#167;</sup>
###xml 270 272 214 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
dagger,double dagger,section signThe risk ratio was first calculated separately for each genotype and genotype combination. Second, the test for interaction between the risk ratios was performed by Cox regression: daggerP = 0.27, double daggerP = 0.064, and section signP = 0.018. The risk ratio for patients not receiving tamoxifen (Tam-) is calculated as 1.0.
###end p 78

